Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NTX-748
- Development stage
- Preclinical
- Lead developer
- Napa Biosciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
NTX-748 is an orally available small molecule inhibitor of CD38 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1), an enzyme that consumes NAD+ and is ubiquitously expressed on immune cells. Developed by Juvenescence through its portfolio company Napa Therapeutics, NTX-748 is being investigated for the treatment of rheumatoid arthritis, where CD38 expression is known to increase. By inhibiting the enzymatic activity of CD38, the drug aims to increase cellular NAD+ levels and modulate inflammatory processes. Preclinical studies in collagen-induced arthritis mouse models have demonstrated that NTX-748 provides dose-dependent beneficial effects, reducing clinical arthritis scores and disease incidence without significant toxicity.
02
Targets
CD38 (Cluster of Differentiation 38)
Beyond the preview
Go deeper on NTX-748.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NTX-748.